NSE filing, NSE: STAR. Summary written from the filing by ALFA Finder's alert engine.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,085.60
- Market cap
- ₹10,006 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.3×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Other Announcement
Strides Pharma Science Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Business Update
Strides Pharma Science received a USFDA Establishment Inspection Report (EIR) for its Bengaluru facility. This confirms the successful closure of the recent cGMP inspection.
Strides Pharma Science Annual General Meeting
Strides Pharma Science Ltd held its 35th Annual General Meeting on August 14, 2026. The meeting transacted ordinary and special business items.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Other merger & restructuring announcements
All →Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr
Vraj Iron & Steel Merger & Restructuring Worth ₹4.55 Cr
Vraj Iron and Steel transferred 396,000 MVK Industries shares to promoter Gopal Sponge for Rs 4.55 Crore. The sale was completed on October 28, 2026.
- Value
- ₹4.55 Cr
KPIT Technologies Merger & Restructuring Worth ₹19.2 Cr
KPIT Technologies will incorporate a new Vietnam subsidiary for mobility engineering, with 100% control. The company commits USD 2 million (about Rs 19.20 Crore) in cash.
- Value
- ₹19.20 Cr